Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)

European Journal of Heart Failure

Volumn 16, Issue 7, 2014, Pages 778-787

  Böhm, Michael ^a   Perez, Ana Cristina ^b   Jhund, Pardeep S ^b   Reil, Jan C ^a   Komajda, Michel ^c   Zile, Michael R ^d   McKelvie, Robert S ^e   Anand, Inder S ^f   Massie, Barry M ^g   Carson, Peter E ^h   McMurray, John J V ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c SORBONNE UNIVERSITÉ   (France)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

Author keywords

Heart failure; Heart rate; Irbesartan; Morbidity; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; IRBESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; SINUS RHYTHM; CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; BIPHENYL COMPOUNDS; FEMALE; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STROKE VOLUME; TETRAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84903783275     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.85     Document Type: Article

References (27)

1. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ,. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29: 1327-1334. (Pubitemid 351768127)
2. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 817-821.
3. Böhm M, Swedberg K, Komajda M, Borer J, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894.
4. Swedberg K, Komajda M, Böhm M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised-placebo-controlled study. Lancet 2010; 376: 875-885.
5. McMurray JJ, Adamopoulus S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
6. Carson PE, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G, for the I-PRESERVE Investigators. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576-585. (Pubitemid 41463727)
7. Massie B, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
8. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM,. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008; 10: 149-56. (Pubitemid 351227428)
9. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM,. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011; 4: 27-35.
10. Fosbol EL, Seibaek M, Brendorp B, Moller DV, Thune JJ, Gislason GH, Torp-Pedersen C, Køber L, Danish Investigations and Arrhythmia ON Dofetilide Study Group. Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study. Int J Cardiol 2010; 140: 279-286.
11. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pfeffer MA, McMurray JJ, Solomon SD, CHARM Investigators. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59: 1785-1795.
12. Maeder MT, Kaye DM,. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. Int J Cardiol 2012; 155: 249-256.
13. Kapoor JR, Heidenreich PA,. Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail 2010; 16: 806-811.
14. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK,. Detection of low phosphocreatinine to ATP ratio in failing hypertrophied human myocardium by P magnetic resonance spectroscopy. Lancet 1991; 338: 973-976.
15. Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A,. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 2004; 308: 236-240. (Pubitemid 38090723)
16. Hasenfuss G, Holubarsch C, Herrmann HP, Astheimer K, Pieske B, Just H,. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994; 15: 164-170. (Pubitemid 24110691)
17. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR,. Altered myocardial force-frequency relation in human heart failure. Circulation 1992; 85: 1743-1750.
18. Zile MR, Baicu CF, Gaasch WH,. Diastolic heart failure abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
19. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA,. Effective arterial elastance as index of arterial vascular load in humans. Circulation 1992; 86: 513-521.
20. Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M,. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013; 62: 1977-1985.
21. Reil JC, Hohl M, Reil GH, Granzier HL, Kratz MT, Kazakov A, Fries P, Müller A, Lenski M, Custodis F, Gräber S, Fröhlig G, Steendijk P, Neuberger HR, Böhm M,. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2013; 34: 2839-2849.
22. Flather M, Shibata M, Coats A, van Veldhuisen D, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of Nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. (Pubitemid 40222359)
23. van Veldhuisen D, Cohen-Solal A, Böhm M, Anker S, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009; 53: 2150-2158.
24. Yamamoto K, Origasa H, Hori M, on behalf of the J-DHF investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118.
25. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH,. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013; 62: 1330-1338.
26. Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, Weaver R, Ahmed I, Frenneaux M,. Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3: 29-34.
27. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM,. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56: 845-54.